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KBG syndrome is characterized by intellectual disability associated with macrodontia of the upper central incisors as well as distinct
craniofacial findings, short stature, and skeletal anomalies. Although believed to be genetic in origin, the specific underlying defect is
unknown. Through whole-exome sequencing, we identified deleterious heterozygous mutations in ANKRD11 encoding ankyrin repeat
domain 11, also known as ankyrin repeat-containing cofactor 1. A splice-site mutation, c.7570-1G>C (p.Glu2524_Lys2525del), cosegre-
gated with the disease in a family with three affected members, whereas in a simplex case a de novo truncating mutation, c.2305delT
(p.Ser769GlnfsX8), was detected. Sanger sequencing revealed additional de novo truncating ANKRD11mutations in three other simplex
cases. ANKRD11 is known to interact with nuclear receptor complexes to modify transcriptional activation. We demonstrated that
ANKRD11 localizes mainly to the nuclei of neurons and accumulates in discrete inclusions when neurons are depolarized, suggesting
that it plays a role in neural plasticity. Our results demonstrate that mutations in ANKRD11 cause KBG syndrome and outline a funda-
mental role of ANKRD11 in craniofacial, dental, skeletal, and central nervous system development and function.First described in 1975, the KBG syndrome (MIM 148550)
is characterized by macrodontia of the upper central
incisors, distinctive craniofacial findings, short stature,
skeletal anomalies, and neurological involvement that
includes global developmental delay, seizures, and intel-
lectual disability.1–4 The etiology is unknown. The initial
description included seven affected patients from three
unrelated families.4 This condition was named KBG
syndrome on the basis of the initials of affected families’
surnames. Transmission from male to male was observed
in two families, suggesting autosomal-dominant inheri-
tance.4,5 Since its initial description, KBG syndrome has
been described in 59 patients in the literature; most of
these cases were simplex, and more males than females
were described. (Table S1, available online). It is likely
that KBG syndrome is underdiagnosed because many of
its features, including intellectual disability, are mild,
and none of the features is a prerequisite for the diagnosis.
The presence of wide upper central incisors (macrodontia),
manifesting after the eruption of the permanent maxillary
incisor teeth, is distinctive although not a sufficient sign
for diagnosis.6,7 On the basis of a review of 46 cases, it
has been suggested that four out of eight major criteria,
namely macrodontia, characteristic facial appearance,
neurological involvement, delayed bone age, short stature,
hand findings, costovertebral anomalies, and the presence
of a first-degree relative with the syndrome, be present for
the diagnosis.31John P. Hussman Institute for Human Genomics, University of Miami Miller S
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The AmericWe ascertained ten families who were from Turkey and
Italy whose cases had been published previously1,5 or who
showed a close resemblance to previously described
patients with KBG syndrome (Table 1, Figure 1, and Table
S1). All patients were evaluated by experienced clinical
geneticists to exclude other syndromic forms of intellectual
disability. Results of chromosomal studies were normal in
each affected individual. This study was approved by the
institutional review board at the University of Miami and
all participating individuals provided written informed
consent. Peripheral blood samples were obtained for DNA
and RNA extraction.
Family 1 included a previously published affected father
and his two affected sons.5 DNA samples of the affected
father and one affected son (individuals I-1 and II-2 in
family 1; Figure 1) and a simplex case (individual 1 in
family 2) were screened with whole-exome capture fol-
lowed by next-generation sequencing. Roche EZ Exome
v2.0 kit was used for extracting the target regions from
genomic libraries for exome sequencing. Each captured
sample was run on two lanes of an Illumina GAIIx plat-
form, which allows 75 bp paired-end reads. Raw data
were analyzed with v1.7 of the Illumina analysis pipeline.
Sequence reads were aligned to reference human genome
with the Mapping and Assembly with Quality (MAQ) soft-
ware v0.7.1. Variant calls were also made with MAQ and
annotated with SeattleSeq into functional categories such
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Table 1. Phenotypic Findings and Identified ANKRD11 Mutations in Study Subjects
KBG SYNDROME
Family 1 Family 2 Family 3 Family 4 Family 5















Country of origin Turkey Turkey Turkey Italy Italy
Sex M M M M M M M
Macrodontiac þ þ þ þ þ þ not applicaple
Craniofacial
findings
low anterior and posterior hairlines, brachycephaly,
triangular face, synophrys, long palpebral fissures,
hypertelorism, ptosis, prominent nasal bridge,
anteverted nostrils, long philtrum, large
and prominent ears
triangular face with











rotated ears, long philtrum,
short and webbed neck








low anterior and posterior
hairlines, triangular face with
pointed chin, synophrys,




philtrum, tented upper lip,
prominent ears
Hand findings short hands with clinodactyly of the 5th fingers
and ulnar deviation of the 2nd fingers
short hands with clinodactyly
of the 5th fingers and ulnar
deviation of the 2nd fingers,
cutaneous syndactyly




short hands with clinodactyly
of the 5th fingers, cutaneous
syndactyly of fingers and toes
short hands with clinodactyly
of the 5th fingers and ulnar
deviation of the 2nd fingers























accessory cervical ribs  accessory cervical ribs 
First-degree relative
with KBG





cryptorchidism cryptorchidism  cryptorchidism
a Previously published.5
b Previously published.1
c Permanent central incisor size isR10 mm in males andR9.7 mm in females. The following abbreviations are used: NA, not available; ID, intellectual disability; ADHD, attention deficit hyperactivity disorder; CSB, closed




















































Figure 1. Phenotypic Features of KBG Syndrome
Written consents were obtained from all participants for publication of clinical images. Distinct facial features of KBG syndrome
include a triangular face, low anterior and posterior hairlines, synophrys, hypertelorism, eyelid ptosis, a broad and high nasal bridge,
an upturned nose, a long philtrum, and wide permanent central incisors (R10 mm in males and R9.7 mm in females). Hand anom-
alies include brachydactyly, clinodactyly, and cutaneous syndactyly. Photographs were taken when individuals in family 1 were
25 years old (II-1), 22 years old (II-2), and 46 years old (I-1) and individual 1 in family 2 was 9 years old. Facial and dental pictures
were taken when individual 1 in family 3 was 6 and 11 years old, respectively. Individual 1 in family 4 was 21 years old and individual
1 in family 5 was 9 years old when photographs were taken.
















249 487 11and untranslated regions. A total average of 10.2 Gb of
sequence (67,930,230 pairs of reads) aligned to the exome
target for the samples. An average depth of 1253 and 95%
(>53) coverage of the targeted-exome region were ob-
tained for each sample (Table S2).
DNA variants obtained with exome sequencing were
filtered on the basis of the presence of a variant in the
same gene in all three tested individuals. Only 11 genes
had variants that were nonsynonymous, nonsense, splice
site, or indel-causing frameshifts and were not present in
the dbSNP132 or 1000 Genomes databases (Table 2). We
used Sanger sequencing to confirm variants obtained
through exome sequencing aswell as to evaluate cosegrega-
tion of variants with the phenotype. PCR reactions were
run in 25 ml volume applying a touch-down protocol
and annealing temperatures between 65C and 57C.
We visualized PCR products on agarose gels, cleaned
over Sephadex columns, and applied to BigDye reactions
following the manufacturer’s recommendations (Applied
Biosystems Inc., CA, USA). We used a DNA Sequencer (ABI
3730xl) to detect mutations. Results were visualized with
the Sequencher 4.7 software (Gene Codes Corporation,
MI, USA). Sanger sequencing of these variants showed
that only a single gene, ANKRD11 (MIM 611192; RefSeq
accession numbers NM_013275.4 [mRNA]; NP_037407.4
[protein]), had a variant that cosegregated with the pheno-
type in family 1 as adominant trait andanother variant that
wasdenovo in family2 (Table S3). Therewas aheterozygousThe Americvariant, c.7570-1G>C (p.Glu2524_Lys2525del), affecting
a splice-acceptor site present in all three affected individuals
but absent in the unaffected mother in family 1 (Figure 2).
The second ANKRD11 variant was a heterozygous one
base-pair deletion, c.2305delT (p.Ser769GlnfsX8), identi-
fied in individal 1 of family 2. Both parents were negative
for this mutation.
Sanger sequencing of all exons and intron-exon bound-
ariesofANKRD11was thenperformed inthe remainingeight
probands. Each PCR primer used for Sanger sequencing
(Table S4) was evaluated for homologous sequences in the
genome, and primers specific to ANKRD11 were chosen.
For copy-number changes involving ANKRD11, 12 ng
genomic DNA was used via TaqMan copy-number assays
for ANKRD11 (Hs05397046_cn) (Applied Biosystems Inc.,
CA, USA). For each reaction, 1 ml copy number variationan Journal of Human Genetics 89, 289–294, August 12, 2011 291
Figure 2. ANKRD1 Mutations
(A) Sanger results of identified mutations. Affected residues are
underlined or indicated with arrows.
(B) Quantitative PCR results of ANKRD11 in individual 1 of family
2 with a heterozygous c.2305delT mutation (left) and his unaf-
fected father with homozygous wild-type alleles (right).
(C) Sanger sequencing ofANKRD11 cDNA showing a heterozygous
c.7570-1G>C mutation in individual II-1 in family 1. The deleted
six base pairs correspond to two amino acids (red).
(D) The alignment of a region from the C-terminal repression
domain of ANKRD11 showing the localization of deleted amino
acids (E and K) in family 1 as well as themutation site in Yodamice.
Figure 3. ANKRD11 Domains and Identified Mutations
The positions of the five identified mutations in ANKRD11
domains. The two mutations identified with exome sequencing
are shown with blue characters.(CNV) probes (203, carboxyfluorescein [FAM] labeled), 1 ml
RNaseP probe mix (203, VIC labeled), 10 ml TaqMan
Universal PCR Master mix (23), 1 ml genomic DNA, and
7 ml of water were mixed with a final reaction volume to
20 ml. Reactions were held at 95C for 10 min, 40 cycles of
95C for 15 s, and 60C for 1 min. Samples were run on the
ABI7900HT Fast real-time PCR system and analyzed with
SDS 2.3 (Applied Biosystems Inc., CA,USA). CopyCaller soft-
ware was used for analyzing qPCR data with a delta
Ct algorithm (Applied Biosystems Inc.,CA, USA). Sanger
sequencing revealed heterozygous truncating mutations in
three simplex cases in families 3, 4, and 5 (Figure 2). Parents
of these patients did not have identifiedmutations, showing
that the mutations were de novo. All five ANKRD11
mutations were negative in ethnicity-matched controls
(Table S5). Sanger sequencing as well as CNV analysis of
ANKRD11 via quantitative PCR remained negative in five
other probands. Families 8 and 9 included affected mother
and son pairs whowere also previously published.1 Another
three families had a single affected individual.
Although the absence of ANKRD11 mutations in half of
our families suggests that KBG syndrome is heterogeneous,
we cannot exclude variants in the regulatory regions of the
gene. Notably, short stature and cryptorchidism were
observed insixof sevenpatientswithanANKRD11mutation,292 The American Journal of Human Genetics 89, 289–294, August 1whereas only one out of five without a mutation had short
stature, and only one of the fourmales without an identified
ANKRD11mutation had cryptorchidism (Table S1).
Four male patients with overlapping de novo microdele-
tions of 16q24.3, whose common region included
ANKRD11 and an adjacent gene, ZNF778, have recently
been reported.8,9 The clinical phenotype included dysmor-
phic facial features with prominent forehead, arched
eyebrows, large ears, and a pointed chin. Recently, another
patient who has similar phenotypic features but in whom
only the 30 end of ANKRD11 is deleted has been reported.10
All patients had been identified because they had autism
spectrum disorder (ASD) and had a mild to moderate
degree of intellectual disability. Other variable features
included congenital heart defects, disorders of neuronal
migration, seizures, cryptorchidism, and kyphoscoliosis.
No information on dental abnormalities was available.
Facial features of these patients resemble those of patients
with KBG syndrome. None of our patients were formally
diagnosed with ASD, although it has been reported in
patients with KBG syndrome11.
ANKRD11 encodes ankyrin repeat domain 11, which is
also known as ankyrin repeat-containing cofactor 1
(ANCO-1). Ankyrin repeat-containing cofactors are known
to interact with the p160 coactivator and nuclear receptor
complex by recruiting histone deacetylases in order
to inhibit ligand-dependent transcriptional activation.12
ANKRD11 contains two transcriptional repression domains
located at the N and C terminals and an activation domain
capable of stimulating transcription13 (Figure 3). Sanger
sequencing of ANKRD11 cDNA obtained from the periph-
eral blood of affected individuals in family 1 showed that
the splice-sitemutation, c.7570-1G>C, leads to an in-frame
deletion of six base pairs that results in a loss of two
amino acids, p.Glu2524_Lys2525del (Figure 2C). These
two amino acids are located in the highly conserved
C-terminal repression domain of ANKRD11 (Figure 2D).
All five ANKRD11 mutations identified in this study are
predicted to affect this domain of the protein. However,
fourmutations are predicted to introduce premature termi-
nation codons, which could trigger nonsense-mediated
mRNA decay and lead to happloinsufficiency of ANKRD11.
Nonsense-mediated decay is more likely to be triggered by
mutations closer to the 50end of the gene. We used real-
time PCR to quantify ANKRD11 expression in peripheral
blood in individual 1 in family 2; he had a heterozygous2, 2011
Figure 4. Activity-Dependent Nuclear
Aggregation of ANKRD11
(A) RT-PCR expression analysis of
ANKRD11 in adult human brain cDNA.
(1) DNA control sample, (2) cDNA sample
with reverse transcriptase, and (3) cDNA
sample without reverse transcriptase in
RT reaction.
(B) Representative image of neonatal
cortical neurons transfected with GFP-
ANKRD11 along with DsRed-MECP2.
Postnatal day 1 neurons (cultured in vitro
for 5 days) were cotransfected with GFP-
ANKRD11 and Ds-Red-MECP2. Twenty-
four hours after transfection, 50 mM
KCl (or 5mM to controls plates) was
added to the culturemedia for 90min, cells
were fixed, stained with antibodies to tyrosinated tubulin (blue), and imaged on a confocal microscope.
(C) Higher magnification image of cotransfected neurons to observe GFP-ANKRD11 nuclear inclusions (arrows). GFP-ANKRD11 (green)
and DsRed-MeCP2 (red) nuclear aggregates do not colocalize.
(D) Representative glial cells (identified by their lack of tyrosinated-tubulin staining) from the same cultures as in (B). Note that in glial
cells, ANKRD11 nuclear inclusions form regardless of KCl addition.c.2305delT mutation, which was the closest mutation to
the 50 end of ANKRD11. Total RNA was extracted from
peripheral blood with a PAXgene blood RNA extraction
kit (QIAGEN, CA, USA), and cDNA synthesis from 1 mg
of total RNA was performed with a First Strand cDNA
Synthesis kit (Roche, SW). For each TaqMan reaction,
40 ng cDNAwasmixedwith TaqManUniversal PCRMaster
Mix (Applied Biosystems Inc., CA, USA), B-actin (VIC
labeled) and ANKRD11 (Hs00203193_m1*-FAM labeled)
probes. PCR conditions were 50C for 2 min, 95C for
10 min, 40 cycles of 95C for 15 s, and 60C for 1 min.
Data were analyzed by SDS 2.3 and RQ manager 1.2
(Applied Biosystems Inc., CA, USA) software. Results
showed that ANKRD11 expression in individual 1 in family
2 was reduced compared to the expression observed in his
unaffected father; this difference suggests that nonsense-
mediated mRNA decay was triggered (Figure 2B). However,
Sanger sequencing of ANKRD11 cDNA in individual 1 in
family 2 demonstrated the mutant allele, indicating that
the mRNA decay is not complete (Figure S1).
Yoda mice are heterozygous for an Ankrd11 missense
mutation, which is only one amino acid away from the
two amino acids deleted by the splice-site mutation in
family 1 (Figure 2D). They present with craniofacial anom-
alies that include deformed nasal bones, shortened snouts,
and wider skulls14 and are similar to the craniofacial
anomalies seen in KBG syndrome. Kyphoscoliosis, as well
as reduced bone mineral density, develop with age in
Yodamice but no other costovertebral anomalies or macro-
dontia were reported. The oldest patient in our study
was 46 years old (individual I-1 in family 1), had a heterozy-
gous p.Glu2524_Lys2525del mutation, and developed
moderate kyphosis and osteopenia (his T-score was 1.6
at L1–L4) with age. It is interesting to note the presence of
typical phenotypic features in both patients and in Yoda
mice with mutations affecting only the C-terminal repres-
siondomain of ANKRD11. Although thesemutations could
conceivably destabilize the entire protein, it is possible thatThe Americthe impaired function of this domain is sufficient to
produce the KBG phenotype.
Little is known about the putative brain-related function
of ANKRD11. Data available from the Human Protein Atlas
(ENSG00000167522) suggest that ANKRD11 is expressed
in the brain at comparatively high levels. To start investi-
gating the functional role of ANKRD11 in the central
nervous system, we first confirmed that it was expressed
in the human brain via nonquantitative RT-PCR analysis
by using ANKRD11 specific primers and an adult human
brain cDNA library (Figure 4A). ANKRD11 has been shown
to form nuclear inclusions in nonneuronal cell lines.12
Therefore, to determine the subcellular localization of
ANKRD11 in brain cells, we transfected a GFP-tagged
version of ANKRD11 into mouse neonatal cerebral cortical
primary cultures. Primary cortical tissue was dissected from
129/SvEv mouse embryos at postnatal day 1 and cultured
as previously described.15 Dissociated cells were plated
onto poly-d-lysine-coated coverslips on 6-well dishes at
a density of 150,000–200,000/cm2. Cells were maintained
in a neurobasal medium (Invitrogen) with B27 serum-free
supplements (Invitrogen), L-glutamine (0.5 mM), and
penicillin/streptomycin (1%). After 5 days, cultures were
transfected with full-length ANKRD11 fused to GFP (GFP-
ANKRD11, generously provided by Paul Nielsen, Hanson
Institute, Adelaide, Australia) and DsRed-MeCP2 with
a standard calcium phosphate precipitation protocol.16
Twenty-four hours after transfection, cultures were treated
with 50 mM KCl for 24 hr. Transfected cells were identified
by GFP/DsRed expression under confocal fluorescence
microscopy (LSM 710 Laser Scanning Microscope, Zeiss).
We observed that the GFP-ANKRD11 localizes mainly to
the nuclei of neurons (Figure 4B) and glial cells (Figure 4D),
and only a relatively small amount is localized in the cyto-
plasm (data not shown). Epigenetic processes such as
modification of histone acetylation have been implicated
in the changes in gene expression that occur during neural
plasticity. Because it has been reported that ANKRD11an Journal of Human Genetics 89, 289–294, August 12, 2011 293
can recruit histone acetyltransferases10 and deacetylases9
and can interact with the p160 coactivator family, we
examined whether membrane depolarization affected
ANKRD11 subcellular location. Under resting conditions,
ANKRD11 was highly enriched in the nucleus and had
a homogeneously diffused distribution (Figures 4B and 4C).
Depolarizing the cells with 50mMKCl significantly induced
nuclear accumulation of ANKRD11 in discrete inclusions
(Figures 4B and 4C). MeCP2, a transcriptional regulator
also linked to intellectual disability, interacts with histone-
modifying enzymes, is sensitive to neuronal activity, and
accumulates in heterochromatic puncta. Cotransfection of
GFP-ANKRD11 and DsRed-MeCP2 into embryonic cortical
cultures showed that the activity-enhanced ANKRD11-con-
taining inclusionsarenot co-occupiedbyMeCP2, suggesting
that these proteinsmight regulate expression of two distinct
sets of genes. These data suggest thatANKRD11mightpartic-
ipate in the regulation of cellular mechanisms that underlie
activity-dependent plasticity.
In conclusion, our results indicate that ANKRD11muta-
tions are a cause of KBG syndrome and delineate a funda-
mental role of ANKRD11 in craniofacial, dental, skeletal,
and central nervous system development and function.
Further studies are warranted to identify other genetic
defects of this genetically heterogeneous condition.Supplemental Data
Supplemental Data include one figure and five tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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